Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimidex, Faslodex, and Iressa in Breast Cancer
NCT00206414Phase 2Terminated
- Sponsor
- Baylor Breast Care Center
- Start
- Jan 2003
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gefitinib in breast cancer (2 arms), sponsored by Baylor Breast Care Center. Primary endpoint: Clinical response rate of primary breast cancer. Started Jan 2003; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00206414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206414.